ENG
INA
Doctoral Promotion of The First Graduate of the Masters Program Students Towards Doctoral Degrees (PMDSU)
Tuesday, January 11, 2022
Located in the Prof. dr. I Goesti Ngoerah Gde Ngoerah, there has been a Doctoral Promotion exam which was carried out in a hybrid manner on behalf of dr. Gede Febby Pratama Kusuma, S.Ked., M.Biomed with the title "The Effect of MLC901 Therapy on Neutrophil-to-Lymphocyte-Ratio Levels, Platelet-to-Lymphocyte-Ratio, BDNF, MoCA-INA Score, and Barthel-Index of Injured Patients Traumatic Brain." Traumatic brain injury (TBI) is one of the leading causes of death and disability affecting millions of people globally with a significant economic burden. TBI can lead to impaired thinking, physical, and behavioral functions that cause a decrease in the patient's quality of life. Therapeutic management is needed to prevent secondary brain injury after TBI, so as to improve the clinical outcome of TBI patients. Recent pre-clinical studies have found that the phytopharmaceutical supplement MLC901 has potential as a nervous system protector and nervous system growth promoter that can prevent secondary brain injury and improve post-TBI clinical outcomes. This study was conducted to clinically prove the therapeutic potential of MLC901 as a neuroprotective agent and a post-TBI nervous system growth agent and its effect on the clinical outcome of TBI patients.
The main result obtained from this study is that MLC901 therapy is clinically proven to act as a neuroprotective agent after TBI by preventing nervous system inflammation and secondary brain injury. MLC901 therapy has also been clinically proven to act as a growth agent for the nervous system after TBI by increasing levels of a protein that stimulates the growth process of the nervous system. MLC901 therapy has also been clinically proven to improve thinking function and independent function in carrying out daily activities after TBI, so as to improve the clinical outcome of TBI patients.
The novelty of this research has resulted in a new clinical understanding of the MLC901 therapeutic management method to prevent secondary brain injury and improve the clinical outcome of TBI patients. This research also results in a new clinical theoretical understanding of the mechanism of action of MLC901 therapy as a neuroprotective agent through the pathway to prevent inflammation of the nervous system by lowering neutrophil-to-lymphocyte-ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) levels. in TBI patients, so as to prevent secondary brain injury and improve the clinical outcome of TBI patients.
The implication of the results of this study for clinical medical practice is that the administration of MLC901 therapy in moderate-grade TBI cases that do not require surgery can be considered as a permanent treatment in daily medical practice.
The open exam this time was led directly by the Vice Dean for Student Affairs and Information Prof. dr. I Made Ady Wirawan, S.Ked., MPH., Ph.D., with a team of examiners:
1. Prof. Dr. dr. Sri Maliawan, Sp.BS (K), FICS (Promoter)
2. Prof. Dr. dr. Tjokorda Gde Bagus Mahadewa, M.Kes., Sp.BS(K) Spinal, FICS
(Copromoter I)
3. Dr. dr. Ni Nyoman Sri Budayanti, Sp.MK (K) (Copromotor II)
4. Prof. Dr. dr. I Made Jawi, M.Kes
5. Prof. Dr. dr. I Wayan Putu Sutirta Yasa, M.Si
6. Dr. dr. A A. Ayu Putri Laksmidewi, Sp.S (K)
7. Dr. dr. Tjok Gde Agung Senapathi, Sp.An., KAR
8. Dr. dr. Achmad Adam, M.Sc., Sp.BS
9. Dr. drh. Hamong Suharsono, M.Kes
While the academic invitations are:
1. Dr. dr. Desak Made Wihandani, M.Kes
2. Dr. dr. Made Ratna Saraswati, Sp.PD, KEMD., FINASIM
3. Dr. dr. I Wayan Niryana, M.Kes., Sp.BS(K)
4. Dr. dr. I Made Muliarta, S.Ked., M.Kes
5. Dr. dr. I Putu Eka Widyadharma, M.Sc., Sp.S(K)
In this exam, Dr. dr. Gede Febby Pratama Kusuma, S.Ked., M.Biomed graduated as the 332nd Doctoral Graduate of Udayana University with CUMLAUDE predicate and is the first graduate student from the master's program to doctorate for excellent undergraduate (PMDSU) Faculty of Medicine, Udayana University.
Gallery
UDAYANA UNIVERSITY